SCHEMBL6492299

SCHEMBL6492299

Cc1ccc(C(=O)Nc2ccc(N(CCc3cscn3)C(=O)OC(C)(C)C)cc2)c(-c2ccc(C(F)(F)F)cc2)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APOB P04114 3/20 0.39
MTTP P55157 3/20 0.39
GCGR P47871 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
KDM4E B2RXH2 1/20 0.37
HSD17B10 Q99714 1/20 0.37
PTPN1 P18031 2/20 0.36
TRPV4 Q9HBA0 1/20 0.36
NR3C1 P04150 3/20 0.36
POLQ O75417 1/20 0.36
NPC1 O15118 1/20 0.35
GMNN O75496 1/20 0.35
LMNA P02545 1/20 0.35
TP53 P04637 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
HTR1A P08908 1/20 0.35
THRB P10828 1/20 0.35
PIM1 P11309 1/20 0.35
CYP2C9 P11712 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6788065 0.91 SMO (0.42) APOBMTTPSMN1; SMN2KDM4ESMO
SCHEMBL6499127 0.88 APOB (0.39) APOBMTTPGCGRKDM4EPTPN1
SCHEMBL6487631 0.86 NR3C1 (0.41) APOBMTTPGCGRNR3C1HTT
SCHEMBL6491198 0.85 APOB (0.39) APOBMTTPSMN1; SMN2KDM4EPTPN1
SCHEMBL6498587 0.85 APOB (0.44) APOBMTTPGCGRSMN1; SMN2KDM4E
SCHEMBL6500238 0.83 GCGR (0.44) APOBMTTPGCGRSMN1; SMN2KDM4E
SCHEMBL6501858 0.82 GCGR (0.43) GCGRSMN1; SMN2KDM4EHSD17B10NR3C1
SCHEMBL6793528 0.82 NR3C1 (0.41) KDM4ENR3C1NPC1LMNASLC6A3
SCHEMBL6502663 0.81 APOB (0.44) APOBMTTPPTPN1LMNATP53
SCHEMBL6793746 0.79 SMO (0.53) APOBMTTPNR3C1SMO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors DAISO CO., LTD. (JP) 2005-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors APOB, APOL1, CTRB2 APOB 1/4885MTTP 677/4885GCGR 1784/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.